SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending due to speculation around potential hyperscaler deals and its connection to Nvidia's AI initiatives. Community members are actively discussing potential partnerships and the possibility of a short squeeze, fueled by strong price action. The stock is also gaining traction as investors anticipate increased demand for AI infrastructure and data centers.

Bollinger Innovations Inc. operates as an electric vehicle company, which engages in the manufacture of passenger electric vehicles and commercial vehicles. It operates through the Bollinger and Mullen/ELMS segments. The company was founded by David Michery on April 20, 2010 and is headquartered in Brea, CA.

Bollinger Innovations Inc.

Bollinger Innovations Inc

BINI is trending due to a reverse stock split, leading to heavy community discussion around dilution and the company's history of reverse splits. Investors are expressing concerns about long-term value and potential delisting, while some speculate on possible short squeezes or future pumps. The conversation also includes skepticism towards the company's fundamentals and management decisions.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending amid renewed buyout speculation and potential partnerships, particularly involving TikTok or AR technology. Community chatter highlights bullish sentiment, with many anticipating a short squeeze and significant gains. Some investors believe SNAP is undervalued, citing its large user base and potential in augmented reality.

Boxlight Corp. is a technological company, which engages in developing, selling, and providing interactive classroom solutions for the global education market. It also designs, manufactures, and distributes interactive projectors, flat panel displays, touch projectors, touch boards, and MimioTeach through the Boxlight Group and Genesis brands. The company was founded by Herbert Myers and Sloan Myers in 1985 and is headquartered in Duluth, GA.

Boxlight Corporation - Ordinary Shares - Class A

Boxlight Corp

BOXL is trending due to a potential short squeeze, with community members actively discussing key breakout levels and anticipating a run to higher prices. Bullish sentiment seems to be fueled by the stock's low float and recent price momentum, although some caution against chasing the rally without news or strong fundamentals. Some traders are pointing to a recent Google EDLA announcement as a catalyst.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending as traders weigh whether the stock's current levels represent a value opportunity or a potential trap, especially as it trades near multi-year lows. The community is actively discussing TRC Capital's mini-tender offer and its potential impact, with bulls eyeing the dividend yield and possible catalysts like Taylor Swift's upcoming album release at Target.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending as the community discusses its potential for a short squeeze and a climb towards higher price targets. Optimism is fueled by increasing institutional ownership and the company's positioning in the AI sector, with many highlighting the potential for partnerships and new deals. Investors are closely watching resistance levels, anticipating a breakout.

AgriFORCE Growing Systems Ltd. is an agriculture technology company, which engages in the development and utilization of intellectual property (IP) assets for improvement. Its solutions include consulting, air and surface sterilization, and other projects. The company was founded on December 22, 2017 and is headquartered in Vancouver, Canada.

AgriFORCE Growing Systems ltd

AgriFORCE Growing Systems is trending due to news of a potential $550 million capital raise and a shift towards becoming an Avalanche-focused company, attracting attention from major investors. The community is actively discussing the low float and potential for a significant price surge, with some comparing it to other high-flying crypto-related stocks. However, there are also concerns about reverse splits and potential pump-and-dump schemes.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as traders focus on the stock's potential to break through the $7 resistance level and ignite a gamma squeeze, while also noting institutional interest through significant call option activity. Community members are actively discussing the company's potential for securing government contracts related to AI and national security. Some investors are drawing parallels to Palantir and expressing long-term bullish sentiment.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community eagerly anticipates a major partnership announcement, with speculation focusing on institutions like BlackRock, JP Morgan, ADP or even a potential Ripple partnership. Discussions also revolve around upcoming catalysts such as compliance milestones and the launch of a super app, fueling bullish sentiment. Many believe Zebec is undervalued and poised for significant growth.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETR is trending due to noted stock picker Eric Jackson mentioning the stock, generating significant community discussion and a price surge. The community is focused on the low float and potential for rapid gains, while some highlight the company's AI-driven approach to mortgage lending. Broader discussions involve potential interest rate cuts and their impact on the housing and mortgage sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wolfe Research’s Andy Chen cut his rating on 89bio to 'Peer Perform' from 'Outperform'&nbsp;and did not assign a price target after the biotech firm agreed to a $3.5 billion takeover by Roche.&nbsp;<a href="https://stocktwits.com/symbol/ETNB">89bio’s stock</a> surged 85% on Thursday to end at $14.96, its best day on record and the highest level in about a year and a half, before easing 0.03% in after-hours trading.<a href="https://stocktwits.com/news-articles/equity/markets/why-did-89bio-stock-nearly-double-in-value/chDcHJIR3bc">Roche is paying $14.50 a share in cash for 89bio</a>, about 79% above where the stock closed on Wednesday. Investors will also get the chance at another $6 a share in cash if certain milestones are met, though those rights won’t be tradable.&nbsp;On a fully diluted basis, the transaction values 89bio at up to $3.5 billion. An affiliate of Roche will launch a tender offer to acquire all outstanding shares, with closing expected in the fourth quarter, subject to customary conditions. Until then, 89bio will continue to operate independently before joining Roche’s pharmaceuticals division.The acquisition brings Roche 89bio’s late-stage drug candidate Pegozafermin, which is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. MASH is a progressive liver disease characterized by fat accumulation leading to inflammation and tissue damage.According to Koyfin, 89bio’s stock has an average 12-month analyst price target of $30.8, with estimates ranging from $12 to $55. The company is covered by 10 analysts, with seven ‘Buy’ ratings, two ‘Hold,’ and no ‘Sell.’ The average rating is ‘Buy.’&nbsp;On Stocktwits, retail sentiment around 89bio was described as 'extremely bullish' with 'extremely high' message volume, while sentiment on Roche was 'bullish' with 'normal' activity.One user noted that Roche’s purchase of 89bio could be part of a broader strategic shopping spree, adding that Sarepta Therapeutics might be next, given the two companies’ long-standing partnership. The user also suggested that Amgen or Pfizer could make competing offers and stated that they planned to hold their position and watch developments.<stembedurl>https://stocktwits.com/GaborPiscis/message/629152949</stembedurl>Another user wondered whether Tempest Therapeutics might be a possible target for Roche following the 89bio deal.<stembedurl>https://stocktwits.com/Fandango23/message/629193287</stembedurl>While 89bio’s stock has risen 91% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/RHHBY">Roche’s stock</a> has climbed 21% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

While 89bio’s stock (ETNB) has risen 91% so far in 2025, Roche’s stock (RHHBY) has climbed 21% over the same period. (Photo credit: Getty Images)

89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious 

The acquisition brings Roche rights to Pegozafermin, now in late-stage trials for liver disease MASH.

Equity

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline 

Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline. 

Shares of 89bio, Inc. (ETNB) jumped 86% in the pre-market session on Thursday after the company said that it has entered into a merger agreement to be acquired by Roche (RHHBY) for up to $3.5 billion on a fully diluted basis.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.89bio.com/news-releases/news-release-details/89bio-inc-announces-agreement-be-acquired-roche">stated</a> that Roche will acquire it for $14.50 per share in cash at closing, representing a premium of approximately 79% to the stock’s closing price on Wednesday. 89bio shareholders will also receive a non-tradeable contingent value right to receive up to an aggregate of $6 per share in cash receivable upon the achievement of certain milestones.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ETNB">ETNB stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:573/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_at_7_35_04_AM_png_e0cb1a5888.webp" alt="ETNB's Sentiment Meter and Message Volume as of 7:35 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="573" height="59"><figcaption>ETNB's Sentiment Meter and Message Volume as of 7:35 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user urged investors to buy the stock now.<stembedurl>https://stocktwits.com/FlyingChemist01/message/629085636</stembedurl>Another opined that the buyout represents a broader trend in which good biopharmaceutical firms are being acquired.<stembedurl>https://stocktwits.com/John62/message/629085287</stembedurl>Under the deal, an affiliate of Roche will commence a tender offer to acquire all of 89bio’s outstanding shares.The closing of the transaction is expected to occur in the fourth quarter, subject to the fulfillment of all closing conditions. Until then, 89bio will operate as a separate and independent company. After the closing of the deal, 89bio will join the Roche group as part of its pharmaceuticals division.The deal includes 89bio’s Pegozafermin, currently in late-stage trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. MASH is a progressive disease characterized by the accumulation of fat in the liver, leading to inflammation and tissue damage.ETNB stock is up 3% this year but down approximately 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-surge-after-fed-signals-more-rate-cuts-in-2025/chDcuaaR3GC">Dow Futures Surge After Fed Signals Possibility Of More Rate Cuts This Year: META, PLTR, PYPL, GOOGL Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did 89bio Stock Nearly Double In Value Today?

89bio announced that Roche will acquire it for $14.50 per share in cash at closing, representing a premium of approximately 79% to the stock’s closing price on Wednesday.

Citi says SMid biotechs alternative to large caps as it starts coverage

Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to large-cap pharmaceutical firms, particularly amid healthcare policy uncertainties. Citi initiated coverage with Buy ratings on 89bio (NASDAQ:ETNB), price target $25. Apogee (NASDAQ:APOG), price target $95. Avidity, price target $70, BioNTech (NASDAQ:BNTX), price target $145. Kiniksa, price target $40. Kymera, price target $52

Companies developing therapies for metabolic steatohepatitis (MASH) saw strong gains even as Novo Nordisk (<a class="mention" data-mention="$NVO" data-symbol-id="NVO" href="https://stocktwits.com/symbol/NVO" target="_blank">$NVO</a>) announced that its GLP-1 drug, semaglutide, demonstrated “superior improvement” in treating the liver disease in its phase 3 ESSENCE trial.&nbsp;Shares of Madrigal Pharmaceuticals (<a class="mention" data-mention="$MDGL" data-symbol-id="MDGL" href="https://stocktwits.com/symbol/MDGL" target="_blank">$MDGL</a>), which received FDA approval earlier this year for its MASH drug, Rezdiffra, rose by 18% following the announcement, with 89Bio (<a class="mention" data-mention="$ETNB" data-symbol-id="ETNB" href="https://stocktwits.com/symbol/ETNB" target="_blank">$ETNB</a>) and Akero Therapeutics (<a class="mention" data-mention="$AKRO" data-symbol-id="AKRO" href="https://stocktwits.com/symbol/AKRO" target="_blank">$AKRO</a>) seeing gains of 15% and 4%, respectively.Novo Nordisk’s ESSENCE trial, a 240-week, double-blind study involving 1,200 adults with MASH and moderate to advanced liver fibrosis, achieved its primary endpoints.&nbsp;After 72 weeks, patients receiving a weekly dose of 2.4 mg semaglutide showed significant liver fibrosis improvement without worsening steatohepatitis, as well as steatohepatitis resolution with no worsening of liver fibrosis, compared to those on placebo.&nbsp;"We are very pleased about the ESSENCE clinical trial results and the potential of semaglutide to help people living with MASH. Among people with overweight or obesity, one in three live with MASH. This has a serious impact on their health and represents a significant unmet need," said Martin Holst Lange, Novo’s executive vice president.The FDA has yet to approve GLP-1 drugs for MASH, though several early trials have shown promise in reversing the disease’s initial stages.&nbsp;In March, Madrigal’s Rezdiffra became the first FDA-approved treatment for MASH with moderate to advanced liver scarring.&nbsp;On Thursday, Madrigal reported robust quarterly earnings, driven by Rezdiffra sales, which led to raised price targets and positive analyst notes.&nbsp;Canaccord boosted its target on Madrigal to $394, citing confidence in continued revenue growth, while UBS increased its target to $441, highlighting an “underappreciated opportunity” in MASH and potential validation from Novo’s findings.<figure class="image"><a href="https://stocktwits.com/symbol/MDGL"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MDGL_sentiment_and_message_volume_Nov_1_69ab9366a3.png" alt="MDGL sentiment and message volume Nov 1.png" width="1314" height="320"></a><figcaption>MDGL sentiment and message volume Nov 1 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for MDGL remained ‘extremely bullish’ as of Friday afternoon amid a spike in message volume, with many fixated on Thursday’s strong results.<stembedurl>https://stocktwits.com/GXD_Texas/message/590911195</stembedurl>Some were also penciling in the next resistance levels for the stock that broke out over $300 this week.<stembedurl>https://stocktwits.com/TheProphetOfProfit/message/590910821</stembedurl>Madrigal’s stock has surged over 33% year-to-date, significantly outperforming broader market benchmarks.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/epix-stock-falls-after-drug-trial-fails/cJEYt4ERBm">Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade</a>

On Thursday, Madrigal reported robust quarterly earnings, driven by Rezdiffra sales, which led to raised price targets and positive analyst notes.

Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat

In March, Madrigal’s Rezdiffra became the first FDA-approved treatment for MASH with moderate to advanced liver scarring.

89bio, Inc. (NASDAQ:ETNB) Receives $28.83 Consensus Target Price from Analysts

89bio, Inc. (NASDAQ:ETNB - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat Ratings reports. Two...

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the Company or 89bio ) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization...

89bio Inc CEO Rohan Palekar Sells 52,718 Shares

89bio (NASDAQ:ETNB)  Shares Down 6.8%

89bio, Inc. (NASDAQ:ETNB - Get Free Report)'s share price fell 6.8% during mid-day trading on Monday . The stock traded as low as $10.78 and last traded at $10.85. 182,176 shares traded hands during...

89bio (ETNB, $10.71) price exceeded its 50-day Moving Average on April 01, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

89bio Inc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

ETNB
89bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ETNB News

ETNB 89bio Inc